As another example, Zoledronic weakens epithelial-mesenchymal transition (EMT) and restores the chemosensitivity of NSCLC to gefitinib by inactivating the IL-6/JAK/STAT3 pathway [18]. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.